

Infection Prevention and Control of Healthcare Associated Infections in Primary and Community Care

National Clinical Guideline Centre for Acute and Chronic Conditions

3rd Guideline Development Group Meeting

Date and Time: 10th June, 10.30 – 16.00

Place: National Clinical Guideline Centre, 5th Floor, 180 Great Portland

Street

GDG Present: Carol Pellowe (Chair) (CP) (Present for agenda items 1–8)

Ellie Hayter (EH) (Present for agenda items 1–8) Elizabeth Gibbs (EG) (Present for agenda items 1-8) Graham Tanner (GT) (Present for agenda items 1-8) (Present for agenda items 1-8) Michael Nevill (MN) Eugenia Lee (EL) (Present for agenda items 1–8) Brian Pullen (BP) (Present for agenda items 1–8) Sue Wright (SW) (Present for agenda items 1-8) Julian Spinks (JS) (Present for agenda items 1–8)

NCGC Present: Nina Balachander (NB) (Present for agenda items 1–8)

Jennifer Hill (JH) (Present for agenda items 6–8) Lee-Yee Chong (LYC) (Present for agenda items 1–8) Sarah Riley (SR) (Present for agenda items 1–8) Sarah Bermingham (SB) (Present for agenda items 1–8)

In attendance:

NICE Staff: NICE attendee 1	Sarah Dunsdon (SD)	(Present for items 5–8)
External Advisor:		
Co-optees	Daphne Colpman (DC)	(Present for items 1–8)
	Kelly Alexander (KA)	(Present for items 1–8)

Agenda Item:

 Introductions and Apologies: CP welcomed the group to the third GDG meeting and introduced external advisors, DC and KA. The group acknowledged apologies from GDG members Godfrey Smith, Sally Stucke and Zara Head. All attendees introduced themselves and their backgrounds.

Declarations of Interest: CP asked for each GDG member to declare their interests verbally and asked them to complete their forms. Each attending GDG member declared his/her interests in front of all those present.

JS declared a personal pecuniary interest, as he received an honorarium from Pfizer and Novartis for speaking at lectures and advisory boards on overactive bladders. No action for these declarations was deemed necessary.

KA declared a personal pecuniary interest. In the last 12 months she received a consultancy fee for attending an advisory board for pharmacy management sponsored by Baxter, £250. No action for these declarations was deemed necessary.

Agenda Item:

No other GDG members had any conflicts of interest to declare.

Minutes of last meeting: The minutes of the last meeting were reviewed by the group and accepted to be an accurate record.

- 2. **Progress report and main aims of the day:** NB updated the GDG on the progress of the guideline and main aims of the day.
- 3. **Antibiotic prophylaxis:** LYC presented clinical evidence on the use of antibiotic prophylaxis when changing long term urinary catheters (<28days). A summary of grading evidence in GRADE was presented along with terms used for formulating recommendations and rational to address when linking evidence to recommendations. SB subsequently presented the economic evidence relating to this question. This was followed by a general discussion by the GDG to try and formulate a recommendation based on the evidence presented.
- 4. Types of catheters: SR presented an update of the clinical evidence on the types of catheters. SB then proposed an economic model structure for intermittent catheterisation. The GDG had a general discussion to try and formulate a recommendation based on the clinical evidence presented, which they agreed to revisit when the economic model was complete.
- 5. Instillations and washouts: NB presented clinical evidence on whether instillations and washouts reduce catheter associated symptomatic urinary tract infections. SB then presented the economic evidence relating to this question. This was followed by a general discussion by the GDG to try and formulate a recommendation based on the evidence presented.
- 6. Linking evidence to recommendations: The GDG discussed the decisions made during the course of the day in moving from clinical evidence and cost effectiveness questions posed to formulating recommendations.
- 7. **Next Steps:** NB presented the work plan for the next meetings.
- 8. **Any Other Business and Close of meeting:** There was no other business discussed. CP thanked everyone for attending and closed the meeting.

Date of the next meeting:

13 4th GDG – 16th July 2010, 10.00 – 16.00, at National Clinical Guideline Centre, 5th Floor, 180 Great Portland Street